Search

Highlights of Past EHA (HOPE ) Asia 2021 - report

In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.

Read more

“Science is all about synergy” - Francesca Vinchi, woman in hematology/EHA volunteer

This Women’s History Month, we are putting the spotlight on women in hematology. One of them is Francesca Vinchi, also an EHA Volunteer.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

Read more

Starting this November: EHA Guidelines Workshops!

EHA has initiated a series of online workshops dedicated to guidelines (produced or endorsed by EHA) for diagnosis and treatment of hematologic diseases.

Read more

EHA leads Tutorial in Kazakhstan for better understanding of lymphomas

EHA, in collaboration with the Kazakhstan Cancer Society (KCS) and Kazakh Institute of Oncology and Radiology (KazIOR), organized its very first tutorial together on March 14-16 in Almaty, Kazakhstan.

Read more

Professor Degos awarded at the 17th Congress of EHA in Amsterdam

Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.

Read more

The ‘i4MDS’ consortium looks to the future at its second general meeting

Feb 29 2024 Posted in Meeting reports Tagged i4MDS

The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.

Read more